Seattle Genetics, Inc.: PharmaVitae Report

Datamonitor, November 2011, Pages: 34

This analysis examines the historical and forecast performance for Seattle Genetics in the prescription pharmaceutical sector. The profile encompasses key product analysis and forecasts, pipeline assessment, and evaluation of company strategy and financial performance over a 6-year period.

Features and benefits

- Gain insight into Seattle Genetics' strategic outlook across the next 6 years
- Analysis of strategically important company products, supported by patient-based forecasting and key opinion leader interviews

Highlights

Strategic evaluation of Seattle Genetics' outlook for the next six years. Assessment of key strengths, weaknesses, opportunities and threats and appraisal of the company’s product portfolio, pipeline and commercial relationships.

Your key questions answered

- After demonstrating impressive response rates in Phase II trials, see how uptake of Adcetris will drive Seattle Genetics' performance
- Assess the potential of Adcetris based on market size, reimbursement issues, and future indications
- Evaluate the company's long-term prospects, based on a strong technology platform and a long pipeline of innovative antibody-drug conjugates

Executive Summary
Company introduction
Recent developments
Corporate relationships
Strategic overview
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
ABOUT THIS REPORT
PharmaVitae Explorer database
Chapter structure
Sales and product analysis
Financial analysis
Data sourcing
Analyst consensus
SALES AND PRODUCT ANALYSIS
Sales overview
Product analysis
Product sales
Adcetris (brentuximab vedotin)
Hodgkin’s lymphoma background
Anaplastic large cell lymphoma background
Adcetris clinical trials
Hodgkin’s lymphoma pivotal trial
Anaplastic large cell lymphoma pivotal trial
Ongoing and planned clinical trials
Clinical and commercial attractiveness
Key forecasting assumptions
Early-stage products
ASG-5ME
ASG-22ME
SGN-19A
FINANCIAL ANALYSIS
Financial performance overview
Operating costs and profit analysis, 2004–
Operating costs and profit analysis, 2010–
APPENDIX
References
Datamonitor reports
Exchange rates

Customers who bought this item also bought

• Haematology at a Glance. 3rd Edition. At a Glance
• Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans
• Global Resource Sharing
• Pathology at a Glance. At a Glance
• Understanding and Applying Research Design
• Israel Life Sciences Market Analysis
• Generic Defense Strategies: Lifecycle Management Strategies to Maximize Revenue in the Face of Growing Generic Competition
• Exploring the Boundaries of International Criminal Justice
• Indian Sea Training and Simulation Market Assessment
• Understanding Educational Statistics Using Microsoft Excel and SPSS